Fig. 3: In vitro neutralization activity of DONQ52. | Nature Communications

Fig. 3: In vitro neutralization activity of DONQ52.

From: Characterizations of a neutralizing antibody broadly reactive to multiple gluten peptide:HLA-DQ2.5 complexes in the context of celiac disease

Fig. 3

In vitro neutralizing activity of DONQ52 (blue), positive control antibody (DQN0139) (orange), and negative control antibody (Control Ab, anti-keyhole limpet hemocyanin (KLH) antibody) (open square) on NFAT-Luc luciferase activity using αβTCR-knockout Jurkat-NFAT-Luc2 cells. Neutralizing activity against (a) DQ2.5-glia-α1a epitope, (b) DQ2.5-glia-α2 epitope, (c) DQ2.5-glia-ω1 epitope, (d) DQ2.5-glia-ω2 epitope, (e) DQ2.5-hor-3a epitope, (f) DQ2.5-glia-α1b epitope, (g) DQ2.5-glia-γ1 epitope, (h) DQ2.5-glia-γ2 epitope, (i) DQ2.5-glia-γ3 epitope, (j) DQ2.5-glia-γ4a epitope, (k) DQ2.5-glia-γ4d epitope are shown. Peptides used for stimulation and their concentrations are shown in Supplementary Table 6. Inhibitory effect of antibodies on TCR activation (%) of each well was calculated when taking a mean cps (count per second, luciferase activity) of the well in the absence of antigen peptide and antibody as 100 %, and a mean cps of the well in the presence of antigen without antibody as 0 %. Data are from an assay performed in triplicates (n = 3) and are plotted as mean ± SD. l In vitro neutralizing activity of DONQ52 (blue), DQN0139 (orange), and Control Ab (open square) on IL-2 production using human CD4+ T cell expressing TCRs specific for DQ2.5-glia-α2. Inhibitory effect of antibodies on IL-2 production (%) of each well was calculated when taking a mean IL-2 concentration of the well in the absence of 33mer gliadin peptide at 1 μM and antibody as 100%, and a mean IL-2 concentration of the well in the presence of antigen without antibody as 0%. Data are from the assay performed in triplicates (n = 3) and are plotted as mean ± SD.

Back to article page